Meet the MedCity Media Team

And take 2 minutes to help us make MedCityNews.com better for you.

Every year, we ask you to tell us a little about yourself (anonymously) to help us create better, more relevant content and features for you. We consider every response and very much appreciate you taking the time to assist us.

Please click the button above to open a simple, multiple choice survey that should only take 2 minutes to complete.

Thank you,

The MedCity Media Team

LabCorp strikes deal for Alzheimer’s disease diagnostic

7:00 am by | 0 Comments

A brain with Alzheimer's disease.

LabCorp (NYSE:LH) has struck a deal to develop and commercialize a new Alzheimer’s disease diagnostic.

The Burlington, North Carolina lab services and diagnostics company has licensed rights to an Alzheimer’s diagnostic technology from OPKO Health (NYSE:OPK). The deal gives LabCorp exclusive rights to the OPKO technology in North America and the United Arab Emirates. No financial terms were disclosed.

Miami, Florida-based OPKO said that its diagnostic technology detects elevated levels of antibodies that appear to be unique to Alzheimer’s disease. OPKO discovered these antibodies using its proprietary technology platform, which has identified biomarkers for a range of diseases that include cancers, autoimmune diseases, neurodegenerative diseases and infectious diseases. The company is developing diagnostics for nonsmall cell lung cancer among other diseases.

Advertisement

Alzheimer’s disease affects more than 5 million people in the United States and more than 35 million worldwide. There are no specific tests available to detect Alzheimer’s disease and track its progression. Diagnosis is currently conducted by behavioral and cognitive measurements.

Brain scans and spinal fluid analysis come with limitations and may not detect Alzheimer’s at an early stage. Definitive diagnosis of the disease can only come from an examination of a brain tissue sample after death.

“We believe that OPKO’s innovative technology will lead to more accurate diagnoses, more effective treatment and better patient outcomes,” LabCorp CEO David King said in a statement.

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

By Frank Vinluan

Frank Vinluan is the North Carolina Bureau Chief for MedCity News.
More posts by Author

0 comments

Hear the latest news first

Get our daily newsletter or follow us.

 

Advertisement